166 related articles for article (PubMed ID: 33142291)
1. Efficacy of 90Y-Radioembolization in Metastatic Colorectal Cancer Depending on the Primary Tumor Side.
Schindler P; Masthoff M; Harders F; Schmidt HH; Stegger L; Pascher A; Rahbar K; Wildgruber M; Köhler M
Dig Dis; 2021; 39(4):351-357. PubMed ID: 33142291
[TBL] [Abstract][Full Text] [Related]
2. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
[No Abstract] [Full Text] [Related]
3. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.
Schmeel FC; Simon B; Luetkens JA; Träber F; Meyer C; Schmeel LC; Sabet A; Ezziddin S; Schild HH; Hadizadeh DR
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1531-1541. PubMed ID: 28317063
[TBL] [Abstract][Full Text] [Related]
4. 90Y Radioembolization Lung Shunt Fraction in Primary and Metastatic Liver Cancer as a Biomarker for Survival.
Xing M; Lahti S; Kokabi N; Schuster DM; Camacho JC; Kim HS
Clin Nucl Med; 2016 Jan; 41(1):21-7. PubMed ID: 26222534
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of ADC measurements in predicting overall survival in patients undergoing
Alis D; Durmaz ESM; Gulsen F; Bas A; Kabasakal L; Sager S; Numan F
Clin Imaging; 2019; 57():124-130. PubMed ID: 31220677
[TBL] [Abstract][Full Text] [Related]
6. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases.
Martin LK; Cucci A; Wei L; Rose J; Blazer M; Schmidt C; Khabiri H; Bloomston M; Bekaii-Saab T
Clin Colorectal Cancer; 2012 Sep; 11(3):195-9. PubMed ID: 22277350
[TBL] [Abstract][Full Text] [Related]
7. Yttrium-90 Radioembolization as Salvage Therapy for Liver Metastases From Colorectal Cancer.
Kalva SP; Rana RS; Liu R; Rachamreddy N; Dave B; Sharma A; Ganguli S; Rabito C; Kwak E; Blaszkowsky LS
Am J Clin Oncol; 2017 Jun; 40(3):288-293. PubMed ID: 25374143
[TBL] [Abstract][Full Text] [Related]
8. Robust evidence for long-term survival with
Jakobs TF; Paprottka KJ; Raeßler F; Strobl F; Lehner S; Ilhan H; Trumm CG; Fendler WP; Sommer W; Paprottka PM
Eur Radiol; 2017 Jan; 27(1):113-119. PubMed ID: 27059858
[TBL] [Abstract][Full Text] [Related]
9. Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system.
Damm R; Seidensticker R; Ulrich G; Breier L; Steffen IG; Seidensticker M; Garlipp B; Mohnike K; Pech M; Amthauer H; Ricke J
BMC Cancer; 2016 Jul; 16():509. PubMed ID: 27439702
[TBL] [Abstract][Full Text] [Related]
10. Is yttrium-90 radioembolization a viable treatment option for unresectable, chemorefractory colorectal cancer liver metastases? A large single-center experience of 302 patients.
Saxena A; Meteling B; Kapoor J; Golani S; Morris DL; Bester L
Ann Surg Oncol; 2015 Mar; 22(3):794-802. PubMed ID: 25323474
[TBL] [Abstract][Full Text] [Related]
11. Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival.
Maleux G; Deroose C; Laenen A; Verslype C; Heye S; Haustermans K; De Hertogh G; Sagaert X; Topal B; Aerts R; Prenen H; Vanbeckevoort D; Vandecaveye V; Van Cutsem E
Acta Oncol; 2016; 55(4):486-95. PubMed ID: 26625262
[TBL] [Abstract][Full Text] [Related]
12. Factors Affecting Oncologic Outcomes of 90Y Radioembolization of Heavily Pre-Treated Patients With Colon Cancer Liver Metastases.
Kurilova I; Beets-Tan RGH; Flynn J; Gönen M; Ulaner G; Petre EN; Edward Boas F; Ziv E; Yarmohammadi H; Klompenhouwer EG; Cercek A; Kemeny NA; Sofocleous CT
Clin Colorectal Cancer; 2019 Mar; 18(1):8-18. PubMed ID: 30297264
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Survival after Yttrium-90 Radioembolization for Colorectal Cancer Liver Metastases.
Weiner AA; Gui B; Newman NB; Nosher JL; Yousseff F; Lu SE; Foltz GM; Carpizo D; Lowenthal J; Zuckerman DA; Benson B; Olsen JR; Jabbour SK; Parikh PJ
J Vasc Interv Radiol; 2018 Aug; 29(8):1094-1100. PubMed ID: 29754852
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry.
Wong TY; Zhang KS; Gandhi RT; Collins ZS; O'Hara R; Wang EA; Vaheesan K; Matsuoka L; Sze DY; Kennedy AS; Brown DB
BMC Cancer; 2022 Mar; 22(1):224. PubMed ID: 35232410
[TBL] [Abstract][Full Text] [Related]
15. Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect Outcomes.
Sofocleous CT; Violari EG; Sotirchos VS; Shady W; Gonen M; Pandit-Taskar N; Petre EN; Brody LA; Alago W; Do RK; D'Angelica MI; Osborne JR; Segal NH; Carrasquillo JA; Kemeny NE
Clin Colorectal Cancer; 2015 Dec; 14(4):296-305. PubMed ID: 26277696
[TBL] [Abstract][Full Text] [Related]
16. Yttrium-90 radioembolization for colorectal cancer liver metastases in KRAS wild-type and mutant patients: Clinical and ccfDNA studies.
Janowski E; Timofeeva O; Chasovskikh S; Goldberg M; Kim A; Banovac F; Pang D; Dritschilo A; Unger K
Oncol Rep; 2017 Jan; 37(1):57-65. PubMed ID: 28004119
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of intratumoral 99mTc-macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for radioembolization with 90Y-microspheres.
Ulrich G; Dudeck O; Furth C; Ruf J; Grosser OS; Adolf D; Stiebler M; Ricke J; Amthauer H
J Nucl Med; 2013 Apr; 54(4):516-22. PubMed ID: 23447653
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Radioembolization in Patients with Chemorefractory Colorectal Cancer Liver Metastasis: a Single-Center Experience.
Türk G; Eldem G; Kılıçkap S; Bozkurt FM; Salancı BV; Çil BE; Peynircioğlu B; Yalçın Ş; Balkancı F
J Gastrointest Cancer; 2019 Jun; 50(2):236-243. PubMed ID: 29354877
[TBL] [Abstract][Full Text] [Related]
19. Role of yttrium-90 in the management of unresectable hepatocellular carcinoma and hepatic metastases.
Kousik V; Promila P; Verma R; Gupta A
Indian J Gastroenterol; 2016 May; 35(3):179-85. PubMed ID: 27185180
[TBL] [Abstract][Full Text] [Related]
20. Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases.
Chua TC; Bester L; Saxena A; Morris DL
J Cancer Res Clin Oncol; 2011 May; 137(5):865-73. PubMed ID: 20859640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]